CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. ("Obsidianâ€) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced a poster presentation of updated data in patients with immune-checkpoint inhibitor (ICI)-resistant advanced melanoma from the Phase 1 single- center first-in-human (FIH) study and the Phase 1/2 Agni-01 multicenter study of amsoki. ...